Medorbis Trade LLP

Medorbis Trade LLP is a pharmaceutical export company based in Mumbai, Maharashtra, India. Established on May 26, 2018, the company operates under the Corporate Identification Number (CIN) AAM-7117. The registered office is located at 304 Town Centre, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra, 400059.

The ownership structure of Medorbis Trade LLP is predominantly held by its promoters, who own 92.83% of the company. The remaining shares are distributed among public shareholders (4.10%) and other entities (3.07%). The company has a paid-up capital of ₹1,50,000.

Specific details regarding Medorbis Trade LLP's manufacturing facilities, including their locations, capacities, and specializations, are not publicly disclosed. The company's export activities primarily involve finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections. However, information about the manufacturing processes and facilities remains limited.

The leadership team of Medorbis Trade LLP comprises the following designated partners:

• Mohan Babulal Jain
• Manish Babulal Jain
• Aarya Mohan Jain

These individuals have been associated with the company since its inception on May 26, 2018. Aarya Mohan Jain joined as a designated partner on June 2, 2025.

Medorbis Trade LLP's export activities are primarily focused on the oncology segment, with a portfolio comprising finished pharmaceutical formulations such as Fluorouracil, Cisplatin, Etoposide, and Cytarabine. The company's total export value stands at $871,000 USD, with 42 shipments across four products in two therapeutic categories. The top five products include Fluorouracil ($263,000, 2.1% market share), Cisplatin ($209,000, 1.6% market share), Etoposide ($200,000, 1.8% market share), and Cytarabine ($199,000, 1.9% market share). The oncology category accounts for 77.1% of the portfolio, while advanced oncology contributes 22.9%. The company's portfolio is highly concentrated, with the top five products comprising 100% of the export value.

Medorbis Trade LLP has established a presence in emerging markets, particularly in Latin America. The company's export data indicates significant shipments to countries such as Colombia and Nicaragua, with 69.92% and 27.94% of export shipments respectively. While specific details regarding WHO prequalification are not available, the company's engagement in these markets suggests a strategic approach to expanding its footprint in regions with growing pharmaceutical demand.

Medorbis Trade LLP's export strategy appears to be concentrated in select markets, with a significant focus on Latin America. The company's portfolio concentration, with the top five products accounting for 100% of the export value, indicates a specialized approach. This strategy may mitigate risks associated with diversification but could also expose the company to market fluctuations in its primary export destinations.

Specific information regarding Medorbis Trade LLP's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export activities primarily focus on markets outside the United States, and there is no publicly disclosed evidence of FDA approvals or registrations.

Details regarding Medorbis Trade LLP's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly disclosed. The company's export activities are concentrated in markets where such certifications may not be mandatory.

Medorbis Trade LLP operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available. The company's export activities suggest compliance with Indian regulatory requirements, but detailed information is not disclosed.

There are no publicly available records of Form 483 observations, warning letters, or import alerts associated with Medorbis Trade LLP. The company's export activities appear to be conducted without significant regulatory issues; however, specific details are not disclosed.

Medorbis Trade LLP operates in the competitive pharmaceutical export market, focusing on oncology products. While specific competitors are not identified, the company's export data indicates significant shipments to Latin American countries, suggesting competition with other pharmaceutical exporters in these regions. The company's specialized product portfolio may provide a competitive edge in niche markets.

Medorbis Trade LLP's key differentiators include its specialized focus on oncology products and a concentrated export portfolio. This specialization allows the company to leverage expertise in a specific therapeutic area, potentially offering high-quality products tailored to market needs. However, the lack of diversification may expose the company to risks associated with market fluctuations in its primary export destinations.

Medorbis Trade LLP's current strategic direction appears to be focused on exporting finished pharmaceutical formulations in the oncology segment to select international markets. The company's future outlook may involve expanding its product portfolio, diversifying export destinations, and seeking certifications such as WHO prequalification and EU GMP to enhance market access and credibility.

Medorbis Trade LLP's export data indicates a consistent volume of shipments, primarily to Latin American countries. The company's specialization in oncology products suggests a reliable supply chain capable of meeting the demands of its export markets. However, the lack of publicly available information regarding manufacturing facilities and regulatory certifications makes it challenging to fully assess the company's reliability and compliance standards.

Importers should verify the following certifications when considering Medorbis Trade LLP as a supplier:

• FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

• WHO-GMP Certification: Verify compliance with World Health Organization Good Manufacturing Practices.

• EU GMP Certification: Ensure adherence to European Union Good Manufacturing Practices.

• ISO Certifications: Assess quality management and product standards through relevant ISO certifications.

To verify these certifications, importers should request copies of the certificates directly from Medorbis Trade LLP and cross-reference them with the issuing authorities' databases.

When conducting due diligence on Medorbis Trade LLP, importers should consider the following steps:

• Verify Regulatory Compliance: Confirm the company's adherence to relevant regulatory standards in both India and target export markets.

• Assess Manufacturing Capabilities: Evaluate the company's manufacturing facilities, quality control processes, and capacity to meet order requirements.

• Review Financial Stability: Analyze financial statements to assess the company's financial health and ability to fulfill contractual obligations.

• Check References and Reputation: Seek feedback from existing clients and industry peers regarding the company's reliability and product quality.

• Monitor for Red Flags: Be vigilant for any signs of regulatory non-compliance, legal disputes, or financial instability that may pose risks to the partnership.

By following this checklist, importers can make informed decisions and establish secure business relationships with Medorbis Trade LLP.